2004: the research phase begins
2014: the first ECHOPULSE®, treating thyroid nodules and breast fibroadenoma, is delivered
2017: start of the collaboration with the University of Virginia Cancer Center (US) in breast cancer research
2019: SONOVEIN®, our first varicose veins robotic platform, is launched
2022: SONOVEIN HD is launched
2024: SONOVEIN is present in more than 15 countries (Europe, China, USA)
Efficient & Cost-Effective
Sonovein® slashes the need for costly surgical setups. No operating rooms, no surgeons, no anesthesiologists—just one operator and revolutionary ultrasound technology.
The Only Non-Invasive Solution for Providers
Forget incisions and scars. Sonovein® offers complete freedom from the invasiveness of surgery, lasers, or radiofrequency—no tubes, no manual insertions, and no sedation required.
Swift Recovery
Patients can resume their daily activities quickly after treatment[2], making it a seamless addition to their routine.
Future-Ready with AI & Robotics
Sonovein®’s data-driven approach integrates robotics with continuous real-time ultrasound imaging, setting the stage for AI integration and automation.
Martin Deterre
Chief Executive Officer
Christophe Lamboeuf
Chief Financial Officer
Michel Nuta
VP Veins & Chief Medical Officer
Jérémie Anquez
VP Research & Chief Scientific Officer
Gaylord Tallec
VP Operations
Vivien Jourdannaud
VP Regulatory Affairs
Thibault Le Normand
Chief Business Officer
Yann Duchesne
Chairman of the Board
Lijuan Deng
Member of the board
Cédric Bellanger
Member of the board
Claude Lenoir
Member of the board
Mehdi El Glaoui
Member of the Board
